TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

NICORETTE (MINT)

NICOTINE POLACRILEX
Approved 1984-01-13
5
Indications
--
Phase 3 Trials
1
Priority Reviews
42
Years on Market

Details

Status
Over-the-counter
First Approved
1984-01-13
Routes
BUCCAL
Dosage Forms
GUM, CHEWING

Companies

Active Ingredient: NICOTINE POLACRILEX

NICORETTE (MINT) Approval History

Loading approval history...

What NICORETTE (MINT) Treats

5 FDA approvals

Originally approved for its first indication in 1984 . Covers 5 distinct patient populations.

  • Other (5)
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

NICORETTE (MINT) FDA Label Details

Pro

NICORETTE (MINT) Patents & Exclusivity

Latest Patent: Apr 2028

Patents (2 active)

US8323683 Expires Apr 30, 2028
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.